# ABclonal (爱博泰克)
ABclonal (爱博泰克; 武汉爱博泰克生物科技有限公司) is a Chinese life-science tools company founded in 2011 in Wuhan by Zhao Qian (赵骞) and Wu Zhicai (吴知才) that develops and sells research antibodies, molecular enzymes, next-generation sequencing (NGS) products, in vitro diagnostics (IVD) raw materials, and antibody-discovery services.[1](https://abclonal.com.cn/about-us/) • [2](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html) The company is registered in Wuhan's East Lake High-Tech Development Zone (Optics Valley) and remains active as last recorded, with an undated registry snapshot showing the status 存续 (active) and Zhao Qian as legal representative.[3](https://vc.pedaily.cn/company/14727.html)
| Fact | Detail |
|---|---|
| Founded | 22 June 2011 (registry date), Wuhan, by Zhao Qian and Wu Zhicai[3](https://vc.pedaily.cn/company/14727.html) • [2](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html) |
| Sector | Research antibodies, molecular enzymes, NGS, IVD raw materials, antibody-discovery CRO[1](https://abclonal.com.cn/about-us/) |
| Largest round | RMB 1.2 billion Series D, December 2021, co-led by Sequoia China, Luxin Venture Capital, and CMB International[4](https://www.36kr.com/p/1523908373008516) |
| Total raised | RMB 1.8 billion within several years, per the company's own site (self-reported)[1](https://abclonal.com.cn/about-us/) |
| Other backers | LYFE Capital (济峰资本), C&D Emerging Investment, Yuanhe Chenkun, Zhengxingu Capital, Beijing Taikang Investment[5](https://www.ofweek.com/medical/2020-12/ART-8120-1111-30475588.html) • [4](https://www.36kr.com/p/1523908373008516) |
| Footprint | R&D centers in Boston, Shanghai, and Wuhan; sales in 40–50+ countries and regions[6](https://www.ivd.wang/article-3348-1.html) |
| Status | Active (存续), per an undated registry snapshot listing legal representative Zhao Qian[3](https://vc.pedaily.cn/company/14727.html) |
## Founding and history
Zhao Qian and Wu Zhicai had studied at university in Wuhan and returned there in 2011 to start the company with a five-person team. Wu Zhicai has said the motive was that researchers who wanted to buy an antibody had almost no alternative to foreign brands.[2](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html) • [7](https://y.dxy.cn/hospital/5156/883368.html) The founding capital was RMB 50,000.[8](http://www.51qe.cn/yiyaonews/2021-12-11/116315.html)
The company entered the fifth "3551 Optics Valley Talent Program" in 2012, set up a US subsidiary in 2013, built its antibody production base at Optics Valley in 2015, and opened a Boston antibody and protein R&D center in 2016.[8](http://www.51qe.cn/yiyaonews/2021-12-11/116315.html) • [2](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html) It entered the molecular enzyme field in 2018, and in 2019 reported a COVID-19 PCR enzyme raw-material breakthrough that cut raw-material cost tenfold.[2](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html)
## Products, technology and services
ABclonal's catalog spans research antibodies, molecular enzymes, NGS library preparation and automation, IVD raw materials, instruments, consumables, and antibody-discovery services. Its Wuhan base at Optics Valley Bio-city raises more than 20,000 animals a year and lists over 10,000 antibody products, supported by more than 300 R&D staff globally across centers in Boston (antibodies and proteins), Shanghai (molecular enzymes, and NGS), and Wuhan Guanggu (immunology).[1](https://abclonal.com.cn/about-us/)
The company's core platforms are a fourth-generation recombinant rabbit monoclonal antibody platform and a CRISPR-based antibody knockout (KO) validation workflow, described in press coverage as globally leading.[5](https://www.ofweek.com/medical/2020-12/ART-8120-1111-30475588.html) It has also commercialized the ABcellar single-cell library-prep system, the basis of a strategic cooperation with Wuhan Aigenbiotech (爱基百客) around single-cell and multi-omics solutions.[9](https://www.abclonal.com.cn/news/show/451.html) During the pandemic it developed raw materials for COVID nucleic-acid and antigen/antibody tests, including proteinase K.[1](https://abclonal.com.cn/about-us/)
## Funding and investors
ABclonal received angel investment in 2016 and completed seven rounds in the following five years.[8](http://www.51qe.cn/yiyaonews/2021-12-11/116315.html) The two named rounds are:
- Series C, December 2020: RMB 600 million, led by LYFE Capital (济峰资本) with Sequoia Capital China, C&D Emerging Investment (建发新兴投资), and Yuanhe Chenkun (元禾辰坤) participating; HaoYue Capital was the sole financial advisor. Proceeds were earmarked for R&D and IVD raw materials.[5](https://www.ofweek.com/medical/2020-12/ART-8120-1111-30475588.html) Deal databases date the round to 18 December 2020.[3](https://vc.pedaily.cn/company/14727.html)
- Series D, December 2021: RMB 1.2 billion, co-led by Sequoia Capital China, Luxin Venture Capital (鲁信创投), and CMB International Capital, with Zhengxingu Capital (正心谷资本) and Beijing Taikang Investment among the followers.[4](https://www.36kr.com/p/1523908373008516) • [10](https://jifengventures.com/pages/70/) The database date is 8 December 2021.[3](https://vc.pedaily.cn/company/14727.html) Trade coverage described it as a record single round for an Optics Valley bio-company.[7](https://y.dxy.cn/hospital/5156/883368.html)
A C+ round on 22 November 2021 is recorded with the amount undisclosed.[3](https://vc.pedaily.cn/company/14727.html) The company's own site states it completed RMB 1.8 billion of financing within several years; this is a company claim.[1](https://abclonal.com.cn/about-us/) After the D round the company said it would expand investment in antibodies, molecular enzyme reagents, and CRO antibody discovery, building a one-stop "reagents + CRO services + equipment and automation" supplier.[4](https://www.36kr.com/p/1523908373008516)
## Business, customers and traction
In March 2021 ABclonal completed the full acquisition of US-based Yurogen (优睿赛思), bringing the SMab next-generation rabbit monoclonal platform in-house after cooperation begun in 2017, and formally entering the drug-discovery CRO business.[11](https://bydrug.pharmcube.com/news/detail/daa0a3fbe854eeccc977bdedf05cc0b9) • [10](https://jifengventures.com/pages/70/) It also invested in Suzhou Mona (莫纳), Suzhou Jitong (极瞳), and Hubei Xinzongke (新纵科), equipment and automation projects consistent with its stated strategy.[10](https://jifengventures.com/pages/70/) • [12](https://www.vbdata.cn/companyDetail/49f9365468ad481b9e0ee98900aa5b79)
In 2021 the company launched the "10,000-antibody plan" (万抗计划), committing no less than RMB 200 million over three years to release at least 10,000 screened and KO-validated recombinant rabbit monoclonal antibodies to global research and IVD markets.[11](https://bydrug.pharmcube.com/news/detail/daa0a3fbe854eeccc977bdedf05cc0b9) By August 2023 it had listed more than 3,000 monoclonal antibodies and was adding close to 100 new ones per month to its global sales network.[13](http://news.cjn.cn/csqpd/wh_20004/202308/t4658386.htm)
On revenue, coverage around the C round put overseas income at 40% of the total, with North America revenue exceeding RMB 100 million in 2020; by the D round the overseas share was close to 50%.[5](https://www.ofweek.com/medical/2020-12/ART-8120-1111-30475588.html) • [8](http://www.51qe.cn/yiyaonews/2021-12-11/116315.html) • [10](https://jifengventures.com/pages/70/) Hubei media reported revenue growth of about 70% annually over a decade, with roughly 20% of revenue reinvested in R&D; these figures come from profile journalism and are not independently audited.[2](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html) The company has also signed a strategic partnership with Beckman Coulter Life Sciences, which supplies flow cytometry and automation solutions for its antibody and molecular-enzyme development; chairman Zhao Qian and China general manager Zhou Wei signed for ABclonal.[14](https://www.yiqi.com/news/detail_794b036aa25aaac9.html)
Sources differ on market reach: the company's own site says products and services cover more than 40 countries and regions,[1](https://abclonal.com.cn/about-us/) while trade press in 2021–2023 reports a sales network covering more than 50.[6](https://www.ivd.wang/article-3348-1.html)
## How it compares with its peers
Around 2021 the Chinese antibody reagent market was dominated by imports: Abcam, Merck, and Thermo Fisher together held roughly 90% market share, with domestic reagents at 9.8%, concentrated in low-to-mid segments.[8](http://www.51qe.cn/yiyaonews/2021-12-11/116315.html) ABclonal positions itself as a domestic replacement for these brands; Wu Zhicai has stated that around 40% of its products are better than imported alternatives, with the rest on par, a company-founder assessment rather than an independent measure.[6](https://www.ivd.wang/article-3348-1.html) He also notes the global life-science tools market is roughly 90% overseas, framing the ~50% overseas revenue share as an intermediate stage of globalization rather than an endpoint.[7](https://y.dxy.cn/hospital/5156/883368.html)
## Status and recent developments
The registry snapshot shows the entity 武汉爱博泰克生物科技有限公司 as active (存续), registered 22 June 2011 with legal representative Zhao Qian and registered capital of RMB 2.6575 million.[3](https://vc.pedaily.cn/company/14727.html) Post-2023 records are sparse. A deal database records one small strategic investment of RMB 1,499,270 involving Xinzongke dated 18 September 2024.[12](https://www.vbdata.cn/companyDetail/49f9365468ad481b9e0ee98900aa5b79) In April 2025 a life-science tools industry research institute was upgraded into a biotechnology and translational medicine innovation hub, with Wu Zhicai appointed as its director.[6](https://www.ivd.wang/article-3348-1.html) The company continues to operate with three R&D centers, a large Optics Valley production base, sales in more than 50 countries and overseas revenue near 50%, with worldwide one-week delivery claimed.[6](https://www.ivd.wang/article-3348-1.html)
## References
1. [关于我们 – ABclonal 官网](https://abclonal.com.cn/about-us/)
2. [让中国造生命科学工具销往全世界 – 中新网湖北](http://www.hb.chinanews.com.cn/news/2021/1224/368561.html)
3. [爱博泰克 – 投资界](https://vc.pedaily.cn/company/14727.html)
4. [医疗健康行业周报 – 36氪](https://www.36kr.com/p/1523908373008516)
5. [爱博泰克完成6亿元人民币C轮融资 – OFweek/动脉网](https://www.ofweek.com/medical/2020-12/ART-8120-1111-30475588.html)
6. [12亿融资背后 – 体外诊断网](https://www.ivd.wang/article-3348-1.html)
7. [爱博泰克吴知才专访 – 丁香园](https://y.dxy.cn/hospital/5156/883368.html)
8. [引导"生物医药芯片"的国产替代 – 大众医药网](http://www.51qe.cn/yiyaonews/2021-12-11/116315.html)
9. [爱博泰克与爱基百客达成战略合作 – ABclonal](https://www.abclonal.com.cn/news/show/451.html)
10. [爱博泰克完成12亿元人民币D轮融资 – 济峰资本](https://jifengventures.com/pages/70/)
11. [爱博泰克正式完成对美国Yurogen（优睿赛思）的全资收购 – 医药魔方](https://bydrug.pharmcube.com/news/detail/daa0a3fbe854eeccc977bdedf05cc0b9)
12. [爱博泰克 – 动脉网 VBData](https://www.vbdata.cn/companyDetail/49f9365468ad481b9e0ee98900aa5b79)
13. [爱博泰克：将"中国造"生命科学工具销往全世界 – 长江网](http://news.cjn.cn/csqpd/wh_20004/202308/t4658386.htm)
14. [爱博泰克与贝克曼库尔特生命科学达成战略合作 – 仪器网](https://www.yiqi.com/news/detail_794b036aa25aaac9.html)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Life science tools and reagents suppliers*
*Initially written Sep 17, 2026 · Reviewed: Sep 20, 2026 · Edited: Sep 20, 2026; Oct 15, 2026 · Last review: Sep 20, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license